ERBB2 and breast carcinoma: Here, we report the efficacy and safety of capivasertib–fulvestrant versus placebo–fulvestrant in a Chinese cohort of patients with HR-positive/HER2-negative advanced breast cancer whose disease progressed during or after aromatase inhibitor therapy and with or without a CDK4/6 inhibitor.